ArticleThe Lancet. Oncology2022

CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply.

Dean A Fennell et al.PubMed ↗Publisher ↗

No numbers read from the abstract.